Pfizer’s Janus kinase (JAK) inhibitors, including PF-06651600 and PF-06700841, have achieved primary efficacy endpoint of improving hair regrowth in patients with moderate to severe alopecia areata (AA) in phase 2a study.
Bristol-Myers Squibb has reported that its oral, selective tyrosine kinase 2 (TYK2) inhibitor BMS-986165, yielded positive results in a phase 2 trial in patients with moderate to severe plaque psoriasis, by reducing the severity of their skin disorder.
Gilead Sciences and Galapagos’ filgotinib has met its primary and all significant secondary endpoints in a phase 3 study of rheumatoid arthritis.
Xspray Pharma, a product development firm with various product candidates in clinical development, has announced positive data from a clinical bioequivalence study with its lead product candidate HyNap-Dasa.
BeiGene's RAF dimer inhibitor, lifirafenib (BGB-283), will be evaluated in combination with SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, in a phase 1b clinical trial in patients with advanced solid tumors.
Gilead Sciences and Galapagos’ filgotinib has reached its primary efficacy endpoint in active ankylosing spondylitis study (AS).
Biothera Pharmaceuticals has entred into a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI) can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.
AstraZeneca’s lupus drug anifrolumab has failed to meet the primary endpoint in the Tulip 1 phase III trial.
Pfizer said that it is terminating two ongoing trials - B5161002, a phase 2 safety and efficacy study and B5161004, an open-label extension study, which are assessing domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
Sonoma Pharmaceuticals has announced the results from a study, which assessed the use of its proprietary high-strength performance-stabilized HOCl (Hypochlorous Acid) in the management of acne vulgaris.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.